Innovent’s Arcotatug Tavatecan meets Phase 3 G-HOPE-001 gastric-cancer endpoints

The PR Newswire feed (source 2321320) and corroborating context (source 2029185) explicitly report that Innovent’s registrational Phase 3 G-HOPE-001 study met both primary endpoints—progression-free survival and overall survival—with statistically significant and clinically meaningful benefits in previously treated, CLDN18.2-positive advanced gastric or gastroesophageal-junction adenocarcinoma. This is new, forward-looking clinical information that can materially change regulatory and commercialization probabilities, so it is approved and classified as a clinical study development. No numerical effect sizes, regulatory approval, or commercial launch is inferred. Importance is high because this is a dual-positive pivotal readout, while surprise is below the maximum because the context indicates that a favorable interim progression-free-survival result had previously been announced. The timestamp uses the supplied feed timestamp as the best estimate for the public announcement; the exact trial data-cut time is not disclosed. Innovent is the direct stakeholder, Takeda is explicitly linked to the IBI343/TAK-921 program in the provided context, and Bristol Myers Squibb has a clearly overlapping Phase III CLDN18.2 ADC program, creating a defensible competitive read-through. The other listed diagnostics, CDMOs, and broader treatment competitors are too indirect or speculative to approve.